Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ?65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Shitara, KoheiDoi, ToshihikoHosaka, HisashiThuss-Patience, Peter C.Santoro, ArmandoJimenez-Fonseca, PaulaLongo, Federico2024-06-122024-06-1220190732-183X1527-7755https://doi.org/10.1200/JCO.2019.37.15_suppl.4037https://hdl.handle.net/20.500.14551/25937Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2019 -- Chicago, IL[Abstract Not Available]en10.1200/JCO.2019.37.15_suppl.4037info:eu-repo/semantics/closedAccess[No Keywords]Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ?65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.Conference Object3715Q1WOS:000487345805225